SCHEMBL15344969

SCHEMBL15344969

Cc1ccnc(N2CCc3cnccc32)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 2/20 0.48
GRIN2B Q13224 2/20 0.48
GRIN2D O15399 1/20 0.48
GRIN3B O60391 1/20 0.48
GRIN2A Q12879 1/20 0.48
GRIN2C Q14957 1/20 0.48
GRIN3A Q8TCU5 1/20 0.48
ROCK1 Q13464 9/20 0.43
MAPT P10636 2/20 0.41
CCR1 P32246 1/20 0.41
CCR5 P51681 1/20 0.41
CCR8 P51685 1/20 0.41
MAP3K14 Q99558 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15341792 0.82 CYP11B2 (0.39) ROCK1MAP3K14MKNK1MKNK2PTPN11
SCHEMBL17033290 0.75 ROCK1 (0.62) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL17335801 0.70 ROCK1 (0.57) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL28518109 0.70 GRIN2D (0.49) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL29721864 0.70 IDO1 (0.46) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL25390515 0.69 MAP3K14 (0.55) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL30471847 0.69 MAP3K14 (0.55) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL15344937 0.69 MAP3K5 (0.41) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL3782058 0.68 CCR1 (0.52) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL1752197 0.68 CCR1 (0.47) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 GRIN1 793/4885GRIN2B 1505/4885GRIN2D 3637/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 GRIN1 793/4885GRIN2B 1505/4885GRIN2D 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.